Non-small Cell Lung Cancer: Current Updates and Perspectives
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Pulmonology".
Deadline for manuscript submissions: 20 January 2025 | Viewed by 4971
Special Issue Editor
Interests: NSCLC; liquid biopsy; cfDNA; MRD; CTCs; heterogeneity; EMT; TKI
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Lung cancer (LC) is the leading cause of cancer deaths in the world, with a less than 20% 5-year survival rate; this is due to diagnoses in the late stage of the disease. Although tissue biopsy remains the most widely used method for categorizing tumors and therapeutic decisions, liquid biopsy (LB), as a new method of observing tumor genetics and tumor dynamics, has also attracted remarkable interest among the oncology community.
The purpose of this Special Issue, “Non-Small Cell Lung Cancer: Current Updates and Perspectives” is to highlight 1) new personalized medicine methods for improving the diagnosis, treatment, and prognosis of NSCLC patients; 2) new technologies and assays that can achieve optimal sensitivity for the early detection of minimal residual disease (MRD) in NSCLC patients; 3) the importance of liquid biopsy as a new tool in therapeutic decision making; and 4) the rapid development of technology and drugs.
Dr. Athina N. Markou
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- non-small cell lung cancer (NSCLC)
- liquid biopsy
- cell-free DNA (cfDNA)
- minimal residual disease (MRD)
- circulating tumor cells (CTCs)
- heterogeneity
- epithelial–mesenchymal transition (EMT)
- tyrosine kinase inhibitor (TKI)
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.